Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion type Assertion NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_head.
- NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion description "[In this article we describe the variants in genes that influence either the efficacy or toxicity of common drugs used in the treatment of inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn's disease (CD) including sulfasalazine and mesalazine, azathioprine (AZA) and 6-mercaptopurine (6-MP), methotrexate (MTX), glucocorticosteroids (CSs) and infliximab.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_provenance.
- NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion evidence source_evidence_literature NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_provenance.
- NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion SIO_000772 16773681 NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_provenance.
- NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion wasDerivedFrom befree-20140225 NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_provenance.
- NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_assertion wasGeneratedBy ECO_0000203 NP936494.RAAOm_lUedj7NfZST7jAfMVAIeq_lz9ETs0_iQu_4pQT8130_provenance.